MA48919A - Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique - Google Patents

Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique

Info

Publication number
MA48919A
MA48919A MA048919A MA48919A MA48919A MA 48919 A MA48919 A MA 48919A MA 048919 A MA048919 A MA 048919A MA 48919 A MA48919 A MA 48919A MA 48919 A MA48919 A MA 48919A
Authority
MA
Morocco
Prior art keywords
prostamide
ophthalmic compositions
compositions containing
nitric oxide
oxide releasing
Prior art date
Application number
MA048919A
Other languages
English (en)
Other versions
MA48919B1 (fr
Inventor
Marina Do
Frédéric Pilotaz
Julien Saldo
Alan L Weiner
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of MA48919A publication Critical patent/MA48919A/fr
Publication of MA48919B1 publication Critical patent/MA48919B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention propose des compositions ophtalmiques aqueuses sous forme de solution comprenant de l'acide hexanoïque, 6- (nitrooxy) -, (1s, 2e) -3 - [(1r, 2r, 3s, 5r) -2 - [(2z) -7 - (éthylamino) -7-oxo-2-heptén-1-yl] -3,5-dihydroxycyclopentyl] -1- (2-phényléthyl) -2-propén-1-yl ester et macrogol 15 hydroxystéarate comme seul agent solubilisant , et une méthode pour leur préparation.
MA48919A 2018-07-12 2019-07-10 Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique MA48919B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18290082 2018-07-12

Publications (2)

Publication Number Publication Date
MA48919A true MA48919A (fr) 2020-01-15
MA48919B1 MA48919B1 (fr) 2021-02-26

Family

ID=63012964

Family Applications (2)

Application Number Title Priority Date Filing Date
MA052258A MA52258A (fr) 2018-07-12 2019-07-10 Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique
MA48919A MA48919B1 (fr) 2018-07-12 2019-07-10 Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA052258A MA52258A (fr) 2018-07-12 2019-07-10 Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique

Country Status (26)

Country Link
US (4) US10688073B2 (fr)
EP (2) EP3593788B1 (fr)
JP (4) JP6672512B2 (fr)
KR (1) KR20210032435A (fr)
CN (2) CN110237031B (fr)
AR (1) AR115734A1 (fr)
AU (1) AU2019300203A1 (fr)
BR (1) BR112021000240A2 (fr)
CA (1) CA3105989A1 (fr)
CY (1) CY1123706T1 (fr)
DK (1) DK3593788T3 (fr)
ES (1) ES2847853T3 (fr)
HR (1) HRP20210138T1 (fr)
HU (1) HUE052747T2 (fr)
LT (1) LT3593788T (fr)
MA (2) MA52258A (fr)
MD (1) MD3593788T2 (fr)
MX (2) MX2021000411A (fr)
PH (1) PH12020552112A1 (fr)
PL (1) PL3593788T3 (fr)
PT (1) PT3593788T (fr)
RS (1) RS61348B1 (fr)
SG (1) SG11202100064WA (fr)
SI (1) SI3593788T1 (fr)
TW (1) TWI839364B (fr)
WO (1) WO2020011845A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3593788T1 (sl) * 2018-07-12 2021-03-31 Nicox S.A. Oftalmični sestavki vsebujoči prostamid, ki sprošča dušikov monoksid
EP4404936A1 (fr) 2021-09-20 2024-07-31 Nicox SA Prostamide libérant de l'oxyde nitrique utilisé comme agent neuroprotecteur

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
UA100393C2 (ru) 2007-10-16 2012-12-25 Сан Фарма Адвансед Ресьорч Компані Лімітед Новые офтальмологические композиции
AR076731A1 (es) 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
US8795634B2 (en) 2008-09-12 2014-08-05 Critical Pharmaceuticals Limited Absorption of therapeutic agents across mucosal membranes or the skin
BR112012028437A2 (pt) * 2010-05-07 2016-07-19 Sun Pharma Advanced Res Co Ltd solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
JP2014522849A (ja) 2011-06-29 2014-09-08 アラーガン インコーポレイテッド ヒドロキシステアリン酸マクロゴール１５製剤
WO2013017821A1 (fr) 2011-08-02 2013-02-07 Cipla Limited Composition pharmaceutique comportant de l'ébastine et de la fluticasone
CN105012231A (zh) * 2014-04-30 2015-11-04 四川科伦药物研究院有限公司 一种包含PGF2α衍生物的稳定性良好的眼用制剂及其制备方法
CN105380901B (zh) * 2015-11-18 2018-07-17 侯宇华 一种他氟前列素滴眼剂及其制备方法
SI3593788T1 (sl) * 2018-07-12 2021-03-31 Nicox S.A. Oftalmični sestavki vsebujoči prostamid, ki sprošča dušikov monoksid

Also Published As

Publication number Publication date
MA48919B1 (fr) 2021-02-26
JP7080268B2 (ja) 2022-06-03
CN111249228A (zh) 2020-06-09
LT3593788T (lt) 2021-04-12
US20210128458A1 (en) 2021-05-06
US11020368B2 (en) 2021-06-01
CN110237031A (zh) 2019-09-17
CN111249228B (zh) 2022-05-03
JP2024023498A (ja) 2024-02-21
US20210220316A1 (en) 2021-07-22
TWI839364B (zh) 2024-04-21
CA3105989A1 (fr) 2020-01-16
HRP20210138T1 (hr) 2021-03-19
JP2020011955A (ja) 2020-01-23
EP3593788B1 (fr) 2020-10-28
MX2021000411A (es) 2021-03-25
MA52258A (fr) 2021-02-17
SI3593788T1 (sl) 2021-03-31
WO2020011845A1 (fr) 2020-01-16
EP3718535A1 (fr) 2020-10-07
BR112021000240A2 (pt) 2021-04-06
PH12020552112A1 (en) 2021-05-31
TW202019401A (zh) 2020-06-01
JP2020105201A (ja) 2020-07-09
MX2023007091A (es) 2023-06-27
AR115734A1 (es) 2021-02-17
DK3593788T3 (da) 2021-01-11
SG11202100064WA (en) 2021-02-25
JP6672512B2 (ja) 2020-03-25
US20200016108A1 (en) 2020-01-16
PL3593788T3 (pl) 2021-05-31
RS61348B1 (sr) 2021-02-26
JP7397910B2 (ja) 2023-12-13
KR20210032435A (ko) 2021-03-24
US10688073B2 (en) 2020-06-23
AU2019300203A1 (en) 2021-03-04
US20200206176A1 (en) 2020-07-02
ES2847853T3 (es) 2021-08-04
CY1123706T1 (el) 2022-05-27
MD3593788T2 (ro) 2021-03-31
CN110237031B (zh) 2022-02-11
EP3593788A1 (fr) 2020-01-15
JP2022116147A (ja) 2022-08-09
HUE052747T2 (hu) 2021-05-28
PT3593788T (pt) 2021-01-21

Similar Documents

Publication Publication Date Title
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA48919B1 (fr) Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique
MA52680A1 (fr) Méthodes de réduction du besoin de revascularisation artérielle périphérique chez un sujet traité par des statines
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA39018A1 (fr) (aza)pyridopyrazolopyrimidinones et indazolopyrimidinones utilisées comme inhibiteurs de la fibrinolyse
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA46038B1 (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
HK1113971A1 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA34732B1 (fr) Spiro-oxindoles antagonistes de mdm2
MA44206A (fr) Comprimé orodispersible comprenant estetrol
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA46611A (fr) Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs
MA30313B1 (fr) Amines secondaires en tant qu'inhibiteurs de la renine
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
MA40937A (fr) Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
FR3047665B1 (fr) Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine
MA45623A (fr) Traitement d'une maladie vasculaire rétinienne utilisant des cellules progénitrices
MA56540A (fr) Procédés et intermédiaires pour la préparation de 2-(2,6-dichlorophényle))-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl-3,4-dihydroisoquinolin-2(1)-yl]éthénone